BUSINESS SITUATION OF THE GERMAN CHEMICAL-PHARMACEUTICAL INDUSTRY

Quarterly report 2.2024

Startseite

Presse

Pressemitteilungen

Quarterly report 2.2024

LanguageDE

10 September 2024 | Pressemitteilung

Downloads

Headwind for Chemistry and Pharma.

Once more, the mood in our industry has been cooling down noticeably.
Once more, the mood in our industry has been cooling down noticeably.
  • Minor production increase over the previous quarter: +0.8 percent
  • Slight rise in producer prices: +0.8 percent
  • Drop in sales against previous quarter: -0.7 percent
  • Outlook: Production +3.5 percent; the industry’s sales: -1.5 percent

The German chemical-pharmaceutical industry keeps struggling in a difficult environment. The recovery lost in momentum in the 2nd quarter 2024. The reason: German overall industry cut back on production in the past three months and was reserved about orders for chemicals. The demand from abroad was down too. Due to the persistent lack of orders, many chemical plants continued to be underutilised below profitable levels. Moreover, energy and raw material prices went up again most recently. Speaking in metaphors, first cracks are also materialising in the foundations of the pharma business. Foreign sales of pharmaceutical products declined lately. Negative figures were recorded in production as well.

VCI Director-General Wolfgang Große Entrup comments on the industry’s business situation: “Once more, the mood in our industry has been cooling down noticeably, because the global economy failed to gain in speed as had been hoped for. Thus, there are no signs of a sustained upturn in demand up until now. At the same time, competitive pressure is getting stronger. Also, the structural problems at the location Germany remain unsolved. In fact, the announced growth initiative is a step in the right direction. However, the announcement alone has not yet brought about any change in sentiment. Meanwhile, four out of ten industrial companies are thinking about further production cuts, or they are even considering relocations abroad. It is high time to consistently tackle the structural problems in this country at long last. Where the Pharma Strategy is concerned, we still see room for improvement too.”

For the whole year 2024, the VCI maintains its forecast of a production rise by 3.5 percent. Irrespective of falling prices, the industry’s sales are anticipated to grow by 1.5 percent in the present year.

Overview of figures for Q2 2024

  • Production increased by 0.8 percent over the previous quarter so that it was 3.7 percent higher than one year earlier. At 75.1 percent, capacity utilisation in the industry continued to be unprofitable.
  • Producer prices went up by 0.8 percent over the previous three months due to rising costs. However, chemical and pharmaceutical products were still 2.4 percent less expensive than one year ago.
  • Seasonally adjusted, total sales in the chemical-pharmaceutical industry dropped by 0.7 percent to altogether 53.8 billion euros. The previous year’s level was slightly missed too.
  • With some 479,500 staff, employment in the chemical-pharmaceutical industry was kept at a high level only thanks to growth in pharmaceuticals.

The VCI and its sector associations represent the interests of around 2,300 companies from the chemical-pharmaceutical industry and related sectors vis-à-vis politicians, public authorities, other industries, science and media. In 2023, the VCI member companies realised sales of ca. 245 billion euros and employed more than 560,000 staff.

Contact: VCI Press Department, phone: +49 69 2556-1496, e-mail: presse@vci.de
VCI on X

Contact

For questions or suggestions, please feel free to contact us.

 Monika von Zedlitz

Monika von Zedlitz

Pressesprecherin Bildungs-/Forschungspolitik, Verkehrsinfrastruktur/Logistik/TUIS, Genehmigungsverfahren/Anlagensicherheit/Chemieparks, Recht/Steuern, Responsible Care, Expertenticker Umwelt & Sicherheit